Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 has been associated with acute kidney injury and published reports of native kidney biopsies have reported diverse pathologies. Case series directed specifically to kidney allograft biopsy findings in the setting of COVID-19 are lacking. We evaluated 18 kidney transplant recipients who were infected with SARS-CoV-2 and underwent allograft biopsy. Patients had a median age of 55 years, six were female, and five were Black. Fifteen patients developed COVID-19 pneumonia, of which five required mechanical ventilation. Notably, five of 11 (45%) biopsies obtained within 1 month of positive SARS-CoV-2 PCR showed acute rejection (four with arteritis, three of which were not associated with reduced immunosuppression). The remaining six biopsies revealed podocytopathy (n = 2, collapsing glomerulopathy and lupus podocytopathy), acute tubular injury (n = 2), infarction (n = 1), and transplant glomerulopathy (n = 1). Biopsies performed >1 month after positive SARS-CoV-2 PCR revealed collapsing glomerulopathy (n = 1), acute tubular injury (n = 1), and nonspecific histologic findings (n = 5). No direct viral infection of the kidney allograft was detected by immunohistochemistry, in situ hybridization, or electron microscopy. On follow-up, two patients died and most patients showed persistent allograft dysfunction. In conclusion, we demonstrate diverse causes of kidney allograft dysfunction after COVID-19, the most common being acute rejection with arteritis.

**Keywords**

biopsy, clinical research / practice, complication: infectious, infection and infectious agents - viral, kidney (allograft) function / dysfunction, kidney transplantation / nephrology

---

**INTRODUCTION**

Coronavirus disease 2019 (COVID-19) has been associated with acute kidney injury (AKI). Whereas a growing body of literature describes the pathologic findings associated with COVID-19 in native kidney biopsies, there is a paucity of information about COVID-19-associated pathology in kidney transplant patients. To our knowledge, only 15 kidney allograft biopsy findings from

---

**Abbreviations:** ACE2, angiotensin-converting enzyme 2; AKI, acute kidney injury; AMR, antibody-mediated rejection; APOL1, apolipoprotein L1; AT1, acute tubular injury; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; CUIMC, Columbia University Irving Medical Center; DSAs, donor-specific antibodies; FFPE, formalin-fixed paraffin-embedded; IQR, interquartile range; IRB, Institutional Review Board; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TCMR, T cell-mediated rejection; TMA, thrombotic microangiopathy.
COVID-19-infected transplant recipients have been published as case reports \( n = 9 \) or as part of series containing predominantly native kidney biopsies \( n = 6 \).\textsuperscript{1,6-15} These reports (summarized in Table S1) demonstrate a variety of etiologies of allograft dysfunction in the transplanted kidney, including podocytopathies,\textsuperscript{6,9-13} acute rejection,\textsuperscript{1,15} allograft infarction,\textsuperscript{14} thrombotic microangiopathy (TMA),\textsuperscript{7} and acute tubular injury (ATI).\textsuperscript{1,8,15} Direct viral invasion of kidney parenchyma was suggested in two reported cases.\textsuperscript{8,9} Because individual case reports may be subject to publication bias and the timeline relative to COVID-19 infection was not provided consistently, detailed case series devoted to kidney allograft biopsy findings are needed to elucidate the range of kidney manifestations and inform clinical management. Herein, we report the first case series of kidney allograft biopsy findings from recipients with COVID-19.

2 METHODS

From the archives of the Renal Pathology Laboratory at Columbia University Irving Medical Center (CUIMC), we retrospectively identified kidney allograft biopsies from SARS-CoV-2-infected patients procured between 3/2020 and 5/2021. All biopsies were “for-cause” biopsies, largely reflecting elimination of protocol biopsies during the pandemic. Patients were required to have either a positive SARS-CoV-2 PCR by nasal swab within 60 days of biopsy or more than 60 days before biopsy plus no documentation of a subsequently negative PCR test result performed prior to the allograft biopsy \( n = 18 \). We chose this arbitrary period because transplant patients are known to have a prolonged COVID-19 course\textsuperscript{16,17} and the potential duration of COVID-19-related histologic manifestations is unknown.

To be more precise regarding the effects of COVID-19, we divided patients into those who had recent infection (positive PCR ≤1 month of biopsy, \( n = 11 \)), and those with more “remote” infection (positive PCR >1 month of biopsy, \( n = 7 \)). These allograft biopsies were reviewed at CUIMC and included 17 biopsies processed at CUIMC and one biopsy referred to CUIMC for immunostaining for SARS-CoV-2. Three of these biopsies were previously reported by our group.\textsuperscript{7} Clinical and laboratory data were extracted from chart review or provided by the referring physician.

All biopsies were processed for light microscopy and immunofluorescence staining for C4d. A full immunofluorescence panel (IgG, IgM, IgA, C3, C1q, kappa, lambda, fibrinogen, albumin) was performed on all but three patients with minimal proteinuria (<0.2 g/g). Electron microscopic evaluation was performed for six patients. All formalin-fixed paraffin-embedded (FFPE) biopsies underwent immunohistochemical staining for the SARS-CoV-2 nucleocapsid protein (SARS-N-Capsid) using rabbit monoclonal antibody from clone 001 (catalog no. 40143-R001; Sino Biologic, Beijing, People's Republic of China), and 17 FFPE biopsies underwent in situ hybridization for SARS-CoV-2 RNA-encoding spike protein (RNA scope 2.5 LS Probe V-CoV2019-S; catalog no. 848568; Advanced Cell Diagnostics).

In an attempt to identify histologic correlates of COVID-19 in the kidney allograft, we compared biopsy findings in our cohort with recent COVID-19 to these of 14 kidney transplant recipients who had non-COVID pneumonia within 1 month before allograft tissue collection (13 autopsies and 1 “for-cause” biopsy), 13 native kidney biopsies obtained within 1 month of COVID, and all pre-COVID “for-cause” kidney allograft biopsies (protocol biopsies were excluded) reviewed at CUIMC between January 1, 2019 and December 31, 2019 \( n = 538 \). Pneumonia was defined by an infectious disease specialist (MRP) based on a combination of clinical symptoms, and radiographical and microbiological findings.

Continuous data were presented as median and interquartile range (IQR1: 25th percentile, IQR3: 75th percentile). Categorical variables were compared using Fisher’s exact test or chi-squared test when multiple groups were compared. Continuous variables were compared using Mann-Whitney test or Kruskal-Wallis test followed by Dunn’s comparison. The Institutional Review Board (IRB) of CUIMC approved this study (AAAT0009).

3 RESULTS

The 18 patients included in this study had a median age of 55 (IQRs: 50, 61) years. Six of the patients were female and five were Black. Underlying etiologies of native kidney failure included immune complex-mediated glomerulonephritis \( n = 5 \), ANCA-associated glomerulonephritis \( n = 1 \), diabetic nephropathy \( n = 4 \), hypertension \( n = 2 \), smoking-related nodular glomerulosclerosis \( n = 1 \), cystic kidney disease \( n = 2 \), calcineurin inhibitor toxicity following liver transplantation \( n = 1 \), congenital abnormalities \( n = 1 \), and neurogenic bladder \( n = 1 \). Six allografts were from living donors. All patients had comorbidities, including hypertension in 17 and diabetes mellitus in eight (Table 1).

Fifteen patients had developed COVID-19 pneumonia. Using the World Health Organization classification of COVID-19 severity,\textsuperscript{18} one patient was asymptomatic, two were mild, six moderate, four severe, and five critically severe, requiring intubation and mechanical ventilation (Table 1). Allograft biopsies were performed for AKI with proteinuria \( n = 4 \), AKI alone \( n = 11 \), isolated proteinuria \( n = 2 \), and transplant nephrectomy after allograft failure \( n = 1 \).

As demonstrated in Table 2, excluding the three patients who were dialysis-dependent prior to biopsy, the median baseline serum creatinine was 1.5 mg/dL (IQRs: 1.3, 2.2) and the median serum creatinine at biopsy was 2.4 mg/dL (IQRs: 2.1, 2.8). Five patients had nephrotic range proteinuria. Although serial SARS-CoV-2 PCR by nasal swab was not performed for all patients, at least one patient had prolonged PCR positivity for over 6 months (patient #8).

Most kidney transplant recipients with COVID-19 were treated by lowering immunosuppression \( n = 13 \); of which three were lowered following allograft biopsy and/or initiation of therapy with corticosteroids \( n = 8 \), tocilizumab \( n = 3 \), remdesivir \( n = 3 \), and/or bamlanivimab monoclonal antibody \( n = 2 \) (Table 2).
### TABLE 1  Patient demographics

| Pt# | Age (yr) | Sex | Race | Cause of ESRD | Transplant source | Comorbidities | COVID-19 manifestations | WHO classification of COVID-19 severity | Biopsy indication |
|-----|----------|-----|------|---------------|------------------|---------------|------------------------|---------------------------------------|------------------|
|     |          |     |      |               |                  |               |                        |                                       | Biopsies within 1 month of positive PCR |
| 1   | 54       | M   | White| IgAN         | Living           | HTN, obesity  | Asymptomatic           | Asymptomatic                          | AKI              |
| 2   | 51       | F   | Hispanic | SLE | Deceased       | HTN            | Hypoxia respiratory failure requiring intubation | Critically severe | AKI, proteinuria |
| 3   | 50       | M   | Hispanic| DM  | Deceased       | HTN, DM, obesity | Fever                  | Moderate                            | AKI              |
| 4   | 15       | F   | Hispanic| Decreased nephron mass | Deceased | HTN, obesity | Cough, fever, bilateral opacities on imaging | Moderate                            | AKI              |
| 5   | 71       | M   | White | Nodular GS (smoking related) | Deceased | HTN, smoking | Hypoxia              | Severe                               | AKI, proteinuria |
| 6   | 64       | M   | Hispanic| DM  | Deceased       | HTN, DM        | Chest pain, fever, hypoxia, diffuse ground glass appearance on imaging | Severe | Proteinuria |
| 7   | 55       | F   | Black | SLE | Living         | HTN, former smoker | Abdominal pain, diarrhea, chills, hypoxia | Severe | AKI, proteinuria |
| 8   | 54       | F   | Hispanic| PCKD | Deceased | HTN          | Sore throat                     | Mild | AKI              |
| 9   | 22       | M   | Black | MN  | Deceased       | HTN            | Cough, fever, bilateral infiltrates on imaging, requiring intubation | Critically severe | Nephrectomy for allograft failure |
| 10  | 53       | F   | White | DM  | Living         | HTN, DM       | Nausea, vomiting, loss of taste, cough | Moderate | AKI              |
| 11  | 66       | M   | White | PCKD | Deceased       | HTN, DM       | Cough, hypoxia, respiratory failure requiring intubation | Critically severe | AKI              |

**Biopsies >1 month post-positive PCR**

| Pt# | Age (yr) | Sex | Race | Cause of ESRD | Transplant source | Comorbidities | COVID-19 manifestations | WHO classification of COVID-19 severity | Biopsy indication |
|-----|----------|-----|------|---------------|------------------|---------------|------------------------|---------------------------------------|------------------|
| 12  | 61       | M   | Unknown| MN | Living         | DM             | Hypoxia              | Moderate                            | AKI, proteinuria |
| 13  | 61       | M   | Black | HTN | Deceased       | HTN            | Myalgias, cough, fever, hypoxia | Severe | AKI              |
| 14  | 40       | F   | Black | HTN | Deceased       | HTN, DM       | Diarrhea, cough, fever, hypoxic respiratory failure requiring intubation | Critically severe | AKI              |
| 15  | 58       | M   | Black | DM  | Deceased       | HTN, DM       | Fatigue, loss of appetite | Mild | Proteinuria |
| 16  | 45       | M   | Hispanic| Neurogenic bladder | Deceased | HTN | Cough, fever | Moderate | AKI              |
| 17  | 58       | M   | White | Pauci-immune crescentic GN | Living | HTN | Fatigue, cough, fever | Moderate | AKI              |
| 18  | 73       | M   | Hispanic| CNI toxicity | Living | HTN, DM, obesity | Cough, fever, hypoxia, respiratory failure requiring intubation | Critically severe | AKI |

Abbreviations: AKI, acute kidney injury; CNI, calcineurin inhibitor; DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; GN, glomerulonephritis; GS, glomerulosclerosis; HTN, hypertension; IgAN, IgA nephropathy; M, male; MN, membranous nephropathy; PCKD, polycystic kidney disease; PCR, polymerase chain reaction; Pt, patient; SLE, systemic lupus erythematosus; WHO, World Health Organization.
### Table 2: Laboratory findings and follow-up information

| Pt# | Baseline Scr (mg/dL) | Scr at biopsy (mg/dL) | UPCR (g/g) | Urine RBCs/ hpf | Salb (g/dL) | Dialysis at biopsy | Duration of follow-up (days) | Post-COVID−19 therapy | Scr on follow-up (mg/dL) |
|-----|----------------------|-----------------------|------------|----------------|------------|-------------------|-----------------------------|------------------------|------------------------|
| 1   | 1.7                  | 2.6                   | 2          | 60             | 4.5        | No                | 363                         | Tocilizumab, IVIg, thymo, steroids, MMF reduced (after biopsy) | 2.2                    |
| 2   | 1.6                  | 2.4                   | 19.9       | 4              | 2.6        | No                | 387                         | IVIg                   | Graft failure           |
| 3   | 1.1                  | 1.7                   | <0.1       | N/A            | 3.8        | No                | 381                         | Thymo, steroids         | 1.4                    |
| 4   | 0.5                  | 2.1                   | 0.31       | 272            | 4          | No                | 182                         | Steroids, bamlanivimab (8 days before biopsy) | 2.0                    |
| 5   | 1.4                  | 2.5                   | 4.4        | 15             | 3.8        | No                | 103                         | MMF held (after biopsy) | Graft failure           |
| 6   | 2                    | 2.5                   | 9.8        | <5             | 3.2        | No                | 32                          | Tacro and MMF reduced, bamlanivimab (31 days before biopsy) | Death with functioning graft |
| 7   | 1.5                  | 3.3                   | 5.8        | 17             | 2.7        | Yes               | 210                         | Steroids, MMF and prednisone held (after biopsy) | 4.0                    |
| 8   | 2.5                  | 2.9                   | 0.2        | 3              | 4.4        | No                | 392                         | MMF reduced             | 1.2                    |
| 9   | Dialysis             | Dialysis              | N/A        | N/A            | 3.4        | Yes               | 432                         | Hydroxychloroquine, tocilizumab, pip-tazo, azithromycin | Graft failure before biopsy |
| 10  | 1.2                  | 1.8                   | 0.2        | 1              | 4.1        | No                | 377                         | MMF reduced             | 1.5                    |
| 11  | Dialysis             | Dialysis              | 100 mg/dL  | N/A            | 2.9        | Yes               | 75                          | Steroids, MMF held, remdesivir (117 days before biopsy) | Graft failure before biopsy |

#### Biopsies >1 month post-positive PCR

| Pt# | Baseline Scr (mg/dL) | Scr at biopsy (mg/dL) | UPCR (g/g) | Urine RBCs/ hpf | Salb (g/dL) | Dialysis at biopsy | Duration of follow-up (days) | Post-COVID−19 therapy | Scr on follow-up (mg/dL) |
|-----|----------------------|-----------------------|------------|----------------|------------|-------------------|-----------------------------|------------------------|------------------------|
| 12  | 2.6                  | 7.3                   | 9.0        | 3-5            | 3          | No                | 151                         | MMF held               | Graft failure a few days after biopsy |
| 13  | 2.6                  | 3.0                   | 0.2        | 10             | 4.2        | No                | 109                         | Steroids, ceftriaxone, azithromycin, azathioprine held, remdesivir (82 days before biopsy) | 3.1                    |
| 14  | 1.4                  | 2.0                   | N/A        | 3              | 4.1        | No                | 327                         | Tocilizumab, MMF held   | 2.6                    |
| 15  | 2.3                  | 2.3                   | 2.5        | 13             | 4          | No                | 71                          | Steroids, MMF held      | 2.3                    |
| 16  | 1.5                  | 2.2                   | 0.2        | 1              | 4.3        | No                | 373                         | MMF reduced             | 2.0                    |
| 17  | 1.1                  | 1.3                   | 0.1        | 16             | 4.9        | No                | 103                         | MMF held                | 1.24                   |
| 18  | Dialysis             | Dialysis              | 100 mg/dL  | 11             | 2.2        | Yes               | 21                          | Steroids, remdesivir (97 days before biopsy) | Graft failure before biopsy; patient expired 21 days after biopsy |

Abbreviations: hpf, high power field; IVIg, intravenous immunoglobulin; MMF, mycophenolate mofetil; N/A, not available; PCR, polymerase chain reaction; pip-tazo, piperacillin-tazobactam; Pt, patient; RBC, red blood cells; Salb, serum albumin; Scr, serum creatinine; tacro, tacrolimus; thymo, thymoglobulin; UPCR, urine protein to creatinine ratio.
# Table 3 Immunologic Characteristics

| Pt# | Diagnosis                                      | Time post-tx | DSA at transplant | IS          | Inflammatory markers                                      | CNI levels<sup>a</sup> | DSA at Bx | Prior acute rejection |
|-----|-----------------------------------------------|--------------|-------------------|-------------|----------------------------------------------------------|-------------------------|-----------|-----------------------|
| 1   | TCMR, 2A                                       | 1 month      | Pos               | Tacro, MMF, pred | IL-6 7 pg/mL                                              | 11–16.5                | Pos       | No                    |
| 2   | AMR (g3, ptc3) + borderline TCMR              | 9 months     | Pos               | Tacro, MMF, pred | D-dimer >20 ug/mL; CRP >300 mg/L; ESR 75 mm/hr; LDH 625 U/L; IL-6 >315 pg/mL | 5.4–6.3                | Pos       | 1 month post-tx: mild AMR (g1, ptc1) + borderline TCMR |
| 3   | TCMR, 2B                                       | 6 months     | Neg               | Bela, MMF    | N/A                                                      | N/A (Bela<sup>b</sup>) | Neg       | No                    |
| 4   | TCMR, 2B                                       | 7 years      | Neg               | Tacro, pred  | CRP 22mg/L; ESR 66 mm/hr; D-dimer 0.71ug/mL                      | <2.0–14                    | Pos       | 5 years post-tx: AMR (g0, ptc2, C4d3)               |
| 5   | Proliferative GN with masked deposits +TCMR, 2A| 40 days      | Neg               | Bela, MMF    | IL-6 59 pg/ml; IL-2R 390 pg/ml; CRP 141 mg/L; D-dimer 4.57 ug/mL; LDH 312 U/L; ferritin 3394 ng/mL | N/A (Bela<sup>b</sup>) | Neg       | No                    |
| 6   | Collapsing glomerulopathy                      | 1.5 years    | Neg               | Tacro, MMF   | N/A                                                      | 5.8–6.0                | Neg       | 13 months post-tx: mixed AMR (g2, ptc0, C4d1) + borderline TCMR |
| 7   | Recurrent LN with lupus podocytopathy          | 8 years      | Neg               | Tacro, MMF, pred | Ferritin wnl; LDH 469 U/L                                         | 2–11                   | Neg       | No                    |
| 8   | ATI                                            | 53 days      | Neg               | Tacro, MMF   | CRP wnl; ferritin 1677 ng/ml                                         | 8.5–12.5                | Neg       | No                    |
| 9   | Infarction                                     | 3 years      | Neg               | Tacro, pred  | Ferritin 1630 ng/ml; ESR 79 mm/hr; CRP 196 mg/L; D-dimer 4.6 ug/mL; LDH 333 U/L | <2.0–3.1                | Pos<sup>c</sup> | 17 months post-tx mixed: AMR (ptc0-1, C4d3) + borderline TCMR |
| 10  | Transplant glomerulopathy                      | 6 months     | Pos               | Tacro, MMF   | N/A                                                      | 6.8–12.6                | Neg       | No                    |
| 11  | ATI                                            | 5 months     | Pos               | Bela, MMF, pred | Ferritin 345 ng/mL                                              | N/A (Bela<sup>b</sup>) | Neg       | 24 days post-tx Borderline TCMR                   |

**Biopsies >1 month post-positive PCR**

| Pt# | Diagnosis                                      | Time post-tx | DSA at transplant | IS          | Inflammatory markers                                      | CNI levels<sup>a</sup> | DSA at Bx | Prior acute rejection |
|-----|-----------------------------------------------|--------------|-------------------|-------------|----------------------------------------------------------|-------------------------|-----------|-----------------------|
| 12  | Collapsing glomerulopathy                      | 1.5 years    | Neg               | Cyclosporine, MMF, pred | N/A                                      | cyclosporine: 95–163                | Neg       | No                    |
| 13  | Moderate IFTA                                  | 1 year       | Pos               | Bela, IVlg, azathioprine | N/A                                                      | N/A (Bela<sup>b</sup>) | Neg       | 17 days post-tx TCMR, 2A                               |
| 14  | Severe IFTA                                    | 6 years      | Pos               | Bela, MMF, pred | IL-6 >315 pg/mL; ESR 85 mm/hr; Ferritin 4520 ng/mL; LDH 2078 U/L | N/A (Bela; held after COVID) | Neg       | 7 days post-tx AMR(C4d3, ATI)                         |
| 15  | Nodular diabetic GS, Moderate IFTA             | 13 months    | Neg               | Bela, tacrol, MMF | N/A                                                      | N/A (Bela<sup>b</sup>) | Pos       | No                    |
| 16  | Severe arteriosclerosis                        | 3 months     | Neg               | Tacro, MMF   | N/A                                                      | 6.0–11.1                | Pos       | No                    |
| 17  | Mild IFTA                                      | 1 year       | Neg               | Tacro, MMF   | N/A                                                      | 8.7–13.9                | Pos       | No                    |

(Continued)
On analysis of histology results in the biopsies taken within 1 month of positive PCR (n = 11), the most common finding was acute rejection (n = 5, 45%, Table 3, Figure 1A), including three with moderate acute T cell–mediated rejection (TCMR: Banff grades 2B [n = 2] and 2A [n = 1]), one with antibody-mediated rejection (AMR) showing severe peritubular capillaritis and severe glomerulitis, and one with concurrent TCMR (Banff grade 2A) and proliferative glomerulonephritis with masked deposits that were apparent only after performing immunofluorescence on pronase-digested paraffin sections. In the latter biopsy, the arteritis was attributed to TCMR given the absence of deposits in vessel walls by conventional as well as pronase immunofluorescence. The biopsy performed at the time of COVID-19 showed marked increase in intraglomerular monocytes and the new development of arteritis (Figure 1B) compared to a previous biopsy performed several days before COVID-19, which had shown no arteritis but had masked deposits. Notably, this patient was found to have an IgG-kappa M-spike by serum electrophoresis with negative cryoglobulin testing.

For the patients with acute rejection, the time period from initial transplantation to biopsy ranged from 1 month to 7 years (Table 3). Two patients had preformed donor-specific antibodies (DSAs) and remained positive at the time of biopsy while one developed de novo DSAs 2 months prior to the diagnosis of COVID-19 and remained positive at the time of biopsy. Notably, none of these five patients had documented change in the immunosuppression regimen prior to the allograft biopsy (Table 2). Moreover, three of these five patients had no previous episodes of acute rejection and appeared adequately immunosuppressed (one with tacrolimus levels of 11–16.5 ng/mL within 2 weeks prior to biopsy and the other two were on regular belatacept infusion with no missed doses) (Table 3).

Two biopsies revealed podocytopathy, one with collapsing glomerulopathy (Figure 1C) and one with recurrent lupus nephritis with diffuse foot process effacement, consistent with lupus podocytopathy (Figure 1D). The patient with collapsing glomerulopathy (patient #6) was Hispanic and the patient with lupus podocytopathy (patient #7) was Black, whereas both of their donors were Black. Notably, the former had undetectable cytomegalovirus or Epstein-Barr virus DNA in the plasma within 3 months of biopsy and did not have critically elevated blood pressure (in the range of 130 mm Hg systolic), highly elevated tacrolimus levels, or concurrent acute rejection.

Two patients had ATI, one of them (patient #11) had critically severe COVID-19 while the other (patient #8) had mild COVID-19 (Table 1) without elevated tacrolimus levels (Table 3). One patient developed allograft infarction (patient #9). This patient had critically severe COVID-19 and his course was further complicated by long-standing anemia and underlying severe arteriosclerosis. Calcineurin inhibitor-mediated injury is unlikely in this case, as measured tacrolimus levels were low.

One biopsy demonstrated transplant glomerulopathy. This biopsy was performed only 6 months after transplantation as the first posttransplant biopsy. The cause was favored to be related to subacute TMA since DSAs were undetectable, C4d staining was

---

**Table 3** (Continued)

| Pt # | Diagnosis | Time post-tx | DSA at Bx | IS at transplant | Inflammatory markers | CNI levels | DSA at transplant | IS Inflammatory markers | CNI levels | DSA at transplant | IS Inflammatory markers | CNI levels |
|------|------------|--------------|-----------|------------------|---------------------|------------|------------------|------------------------|------------|------------------|------------------------|------------|
| 18   | ATI        | 4 months     | Neg       | Tacro, MMF       | Ferritin 3296 ng/mL | CRP 254 mg/L; LDH 275 U/L | Neg | Tacro, MMF | Ferritin 3296 ng/mL | CRP 254 mg/L; LDH 275 U/L |
| 2.7 to 29 | Neg | No | 2.7 to 29 | Neg | No | 2.7 to 29 | Neg | No |

Abbreviations: AMR, antibody-mediated rejection; ATI, acute tubular injury; Bela, belatacept; Bx, biopsy; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; DSA, donor-specific antibody; ESR, erythrocyte sedimentation rate; g, glomerulitis; GN, glomerulonephritis; GS, glomerulosclerosis; FTB, tubulointerstitial fibrosis; IS, immunosuppression; LDH, lactate dehydrogenase; MMF, mycophenolate mofetil; N/A, not available; Neg, negative; Pred, prednisone; Ptc, peritubular capillaritis; Tacrolimus; TMA, thrombotic microangiopathy; TX, transplant; wnl, within normal limits.

| Pt # | Diagnosis |
|------|------------|
| 18   | ATI        |

*Considered positive since multiple prior values were positive for class II DSA with high MFI 240,000 5 months prior to the current biopsy.

*Did not miss any belatacept infusion subsequent to detection of SARS-CoV-2.

*Calcineurin inhibitor (CNI) levels were assessed between the time of SARS-CoV-2 detection (by polymerase chain reaction) and allograft kidney biopsy, or 2 weeks before the biopsy if SARS-CoV-2 was detected less than 2 weeks before the biopsy. This is mentioned together with any missing doses.

*Considered positive since multiple prior values were positive for class II DSA with high MFI 240,000 5 months prior to the current biopsy.

On analysis of histology results in the biopsies taken within 1 month of positive PCR (n = 11), the most common finding was acute rejection (n = 5, 45%, Table 3, Figure 1A), including three with moderate acute T cell–mediated rejection (TCMR: Banff grades 2B [n = 2] and 2A [n = 1]), one with antibody-mediated rejection (AMR) showing severe peritubular capillaritis and severe glomerulitis, and one with concurrent TCMR (Banff grade 2A) and proliferative glomerulonephritis with masked deposits that were apparent only after performing immunofluorescence on pronase-digested paraffin sections. In the latter biopsy, the arteritis was attributed to TCMR given the absence of deposits in vessel walls by conventional as well as pronase immunofluorescence. The biopsy performed at the time of COVID-19 showed marked increase in intraglomerular monocytes and the new development of arteritis (Figure 1B) compared to a previous biopsy performed several days before COVID-19, which had shown no arteritis but had masked deposits. Notably, this patient was found to have an IgG-kappa M-spike by serum electrophoresis with negative cryoglobulin testing.

For the patients with acute rejection, the time period from initial transplantation to biopsy ranged from 1 month to 7 years (Table 3). Two patients had preformed donor-specific antibodies (DSAs) and remained positive at the time of biopsy while one developed de novo DSAs 2 months prior to the diagnosis of COVID-19 and remained positive at the time of biopsy. Notably, none of these five patients had documented change in the immunosuppression regimen prior to the allograft biopsy (Table 2). Moreover, three of these five patients had no previous episodes of acute rejection and appeared adequately immunosuppressed (one with tacrolimus levels of 11–16.5 ng/mL within 2 weeks prior to biopsy and the other two were on regular belatacept infusion with no missed doses) (Table 3).

Two biopsies revealed podocytopathy, one with collapsing glomerulopathy (Figure 1C) and one with recurrent lupus nephritis with diffuse foot process effacement, consistent with lupus podocytopathy (Figure 1D). The patient with collapsing glomerulopathy (patient #6) was Hispanic and the patient with lupus podocytopathy (patient #7) was Black, whereas both of their donors were Black. Notably, the former had undetectable cytomegalovirus or Epstein-Barr virus DNA in the plasma within 3 months of biopsy and did not have critically elevated blood pressure (in the range of 130 mm Hg systolic), highly elevated tacrolimus levels, or concurrent acute rejection.

Two patients had ATI, one of them (patient #11) had critically severe COVID-19 while the other (patient #8) had mild COVID-19 (Table 1) without elevated tacrolimus levels (Table 3). One patient developed allograft infarction (patient #9). This patient had critically severe COVID-19 and his course was further complicated by long-standing anemia and underlying severe arteriosclerosis. Calcineurin inhibitor-mediated injury is unlikely in this case, as measured tacrolimus levels were low.

One biopsy demonstrated transplant glomerulopathy. This biopsy was performed only 6 months after transplantation as the first posttransplant biopsy. The cause was favored to be related to subacute TMA since DSAs were undetectable, C4d staining was
negative in peritubular capillaries, tacrolimus levels were not highly elevated, and the patient did not have evidence for infection by hepatitis C virus.

The detailed histologic assessment of all allograft biopsies is presented in Table 4. To explore whether some of the observed pathologic findings might be specific for COVID-19, pathologic characteristics of our cohort of kidney allograft biopsies performed within 1 month of positive SARS-CoV-2 PCR test (n = 11) were paralleled first to two comparative groups: (a) 14 transplant patients with non-COVID-19 pneumonia within 1 month of kidney allograft histologic evaluation, and (b) 13 patients who underwent a native kidney biopsy within a month of COVID-19. Transplant patients with COVID-19 tended to have a higher incidence of acute rejection than transplant patients with non-COVID-19 pneumonia (p = .06), which reached statistical significance when the incidence of acute vascular rejection (TCMR grade 2A or above) was compared (OR = 17, p = .03) (Table S2). The incidence of other diagnoses did not reach statistical significance in this small sample. Compared to the other two groups, transplant patients with COVID-19 also had higher Banff scores for arteritis (p = .005), glomerulitis (p = .005), and peritubular capillaritis (p = .02) (Table S2).

In an attempt to confirm the above findings, the incidence of acute rejection and Banff scores associated with acute rejection were then compared with a historic cohort of all kidney allograft biopsies performed for allograft dysfunction that were reviewed at CUIMC in 2019 (n = 538, preceding the COVID-19 pandemic). Again, allograft biopsies from transplant patients with COVID-19 had a significantly higher incidence of acute rejection (OR = 3.5, p = .047), especially acute vascular rejection (OR = 11.6, p = .002) and higher Banff scores for arteritis (p < .001) and, to a lesser extent, glomerulitis (p = .02) (Figure 2, Table S3).

In contrast to biopsies performed within 1 month of COVID-19, biopsies performed >1 month after positive SARS-CoV-2 PCR tended to show more chronic and nonspecific changes (Table 3). Only one additional case of a collapsing glomerulopathy (patient #12) was documented. In this case, the allograft kidney was obtained from a White donor and the biopsy demonstrated severe arteriolar hyalinosis and focal arteriolar thrombi consistent with vaso-occlusion. One biopsy revealed ATI (patient #18). This particular patient had severe COVID-19 and fluctuating tacrolimus levels. The remaining five patients had either nonspecific histologic findings (n = 2) or prominent chronic changes (n = 3), of which two had previous episodes of acute rejection that occurred prior to COVID-19 (Table 3).

When risk factors for acute rejection were compared between patients presenting more than 1 month from COVID-19 and those presenting within 1 month of diagnosis, no significant differences were noted in this small sample (Table S4).

Immunohistochemical staining for SARS-N-Capsid was negative in all 18 biopsies, in situ hybridization for SARS-CoV-2 RNA-encoding spike protein was negative in all of 17 biopsies, and no viral particles
| Pt# | Diagnosis                                      | #glom | #GS | #SS | i | t | g | v | ptc | cg | ct | ci | cv | ah | ti | C4d | IF | EM | IHC/ISH |
|-----|------------------------------------------------|-------|-----|-----|---|---|---|---|-----|----|----|----|----|----|----|-----|----|----|--------|
| 1   | TCMR, 2A                                       | 11    | 1   | 0   | 2 | 2 | 0 | 1 | 2   | 0  | 1  | 1  | 1  | 0  | 2  | 0   |    |    | Neg/Neg |
| 2   | AMR +borderline TCMR                           | 23    | 1   | 0   | 1 | 1 | 3 | 0 | 3   | 0  | 2  | 2 | 0 | 0 | 1 | 0   |    |    | Neg/No VP Neg/Neg |
| 3   | TCMR, 2B                                       | 7     | 0   | 0   | 3 | 3 | 1 | 2 | 0   | 0  | 1  | 1  | 1  | 0  | 3 | 0   |    |    | Neg/N/A |
| 4   | TCMR, 2B                                       | 13    | 2   | 0   | 3 | 3 | 0 | 2 | 2   | 0  | 1  | 1 | 0 |    |    | 0   |    |    | Neg/No VP Neg/N/A |
| 5   | Proliferative GN with masked deposits +TCMR, 2A| 24    | 0   | 0   | 0 | 1 | 3 | 1 | 0   | 2 | 1  | 1 | 0 | 1 | 0 | 0   | IgG 2+, kappa 2+, lambda 1+ |   |    | IgG/2+, kappa 2+, lambda 1+ |
| 6   | Collapsing glomerulopathy                      | 25    | 5   | 4   | 0 | 0 | 2 | 0 | 1   | 2 | 2  | 2 | 2 | 1 | 0 | 1   |    |    | Neg/Neg |
| 7   | Recurrent LN with lupus podocytopathy           | 9     | 5   | 1   | 0 | 1 | 0 | 0 | 0   | 2 | 2  | 1 | 1 | 2 | 0 |   | Sparse deposits along GC |   |    | Neg/Neg |
| 8   | ATI                                            | 20    | 1   | 0   | 0 | 0 | 0 | 0 | 0   | 0 | 0  | 1 | 1 | 0 | 0 | Neg | N/A |    | Neg/Neg |
| 9   | Infarction                                     | NA    | NA  | NA  | 1 | 0 | 0 | 0 | 0   | 3 | 3  | 3 | 1 | 1 | NA| N/A | Neg | N/A | Neg/Neg |
| 10  | Transplant glomerulopathy                      | 24    | 3   | 0   | 0 | 1 | 0 | 0 | 2   | 1 | 1  | 1 | 0 | 0 | 0 | N/A | N/A |    | Neg/Neg |
| 11  | ATI                                            | 11    | 0   | 0   | 0 | 1 | 0 | 0 | 2   | 0 | 1  | 0 | 1 | 1 | 1 | 0   | Neg | N/A | Neg/Neg |
| 12  | Collapsing glomerulopathy                      | 19    | 10  | 3   | 0 | 1 | 0 | 0 | 0   | 0 | 3 | 3 | 0 | 3 | 3 | 1   | Neg | N/A | Neg/Neg |
| 13  | Moderate IFTA                                  | 15    | 0   | 0   | 0 | 1 | 0 | 0 | 0   | 0 | 2 | 2 | 1 | 1 | 0 | 0   | N/A | N/A | Neg/Neg |
| 14  | Severe IFTA                                    | 15    | 8   | 0   | 0 | 0 | 0 | 0 | 1   | 0 | 3 | 3 | 2 | 1 | 0 | N/A | N/A | N/A | Neg/Neg |
| 15  | Nodular diabetic GS, Moderate IFTA             | 25    | 5   | 0   | 0 | 2 | 1 | 0 | 0   | 0 | 2 | 2 | 1 | 2 | 1 | 0   | 35–40% FPE, mesangial expansion, thickened GBMs, No VP |   |    | Neg/Neg |
| 16  | Severe arteriosclerosis                        | 14    | 1   | 0   | 0 | 1 | 0 | 0 | 1   | 0 | 1 | 3 | 2 | 0 | 0 | N/A | 35–40% FPE, mesangial expansion, thickened GBMs, No VP |   |    | Neg/Neg |
| 17  | Mild IFTA                                      | 15    | 4   | 0   | 0 | 0 | 0 | 0 | 0   | 0 | 1 | 1 | 1 | 1 | 0 | 0   | Neg | N/A | Neg/Neg |
| 18  | ATI                                            | 16    | 0   | 0   | 0 | 0 | 0 | 0 | 0   | 0 | 0 | 0 | 0 | 1 | Neg | N/A |    | Neg/Neg |

Abbreviations: ah, arteriolar hyalinosis; AMR, antibody-mediated rejection; ATI, acute tubular injury; cg, chronic transplant glomerulopathy; ci, interstitial fibrosis; ct, tubular atrophy; cv, arterial fibrous intimal thickening; EM, electron microscopy; FPE, foot process effacement; g, glomerulitis; GBM, glomerular basement membrane; GC, glomerular capillaries; glom, glomerulitis; GN, glomerulonephritis; GS, glomerular sclerosis; i, interstitial inflammation; IF, immunofluorescence; IFTA, interstitial fibrosis and tubular atrophy; IgA, immunoglobulin A; IgG, immunoglobulin G; IHC, immunohistochemical staining for SARS-CoV-2; ISH, in situ hybridization for SARS-CoV-2; LN, lupus nephritis; N/A, not available; Neg, negative; PCR, polymerase chain reaction; Pt, patient; ptc, peritubular capillaritis; SS, segmental sclerosis; t, tubulitis; TCMR, T cell-mediated rejection; ti, total inflammation; v, intimal arteritis; VP, viral particles.
were seen in all six biopsies studied by electron microscopy (Table 4, Figure S1).

The follow-up period ranged from 1 to 14 months (median 210 days, IQRs: 103, 377). Two patients died (21 and 32 days after biopsy, Table 2). Death was attributed to gram negative sepsis in one patient (#18) and unknown causes in the other (patient #6) who was found unresponsive at home. Three patients were on dialysis at the time of the allograft biopsies and never recovered graft function, and three additional patients developed graft failure on follow-up (Table 2). Only two of the studied patients demonstrated marked improvement in kidney function approaching baseline levels.

4 | DISCUSSION

COVID-19 has been demonstrated to result in high morbidity and mortality in kidney transplant patients, with a mortality rate of 24% as compared to 1% in the general population.20 While the mass deployment of vaccination against SARS-CoV-2 is encouraging, the transplant population remains vulnerable. Preliminary studies on the efficacy of the mRNA vaccines on immunosuppressed patients suggest a weakened antibody response as compared to the general public.21,22 Until larger herd immunity is achieved or advances are made in dosing of the vaccine in transplanted patients, the dangers of COVID-19 and its effects on the kidney allograft are likely to persist.

AKI is reported to be a significant consequence of COVID-19 that affects both native and transplanted kidneys. Current theories regarding the cause of AKI in transplant patients with COVID-19 include direct viral invasion,8,9 possibly via the angiotensin-converting enzyme 2 (ACE2) receptor, or indirect allograft damage related in part to virus-induced systemic cytokine storm.12 A number of series have been published regarding histologic findings in the native kidney of patients infected with SARS-CoV-2; however, a clear etiologic link is not always demonstrable. Even less information exists for the transplant population.

This series of kidney transplant recipients who underwent allograft biopsy after COVID-19 demonstrates a variety of causes of allograft dysfunction with a relatively poor outcome. Distinct disease entities were more frequent in biopsies obtained within 1 month of positive SARS-CoV-2 PCR compared to those obtained at later time points. During follow-up, two patients died and most

![Figure 2](https://example.com/figure2.png)

**Figure 2** Comparison of pathologic findings in allograft biopsies within 1 month of COVID-19 and total “for-cause” kidney transplant biopsies. Histologic findings were compared between our cohort of allograft biopsies performed within 1 month of positive SARS-CoV-2 PCR (n = 11) and all “for-cause” allograft biopsies that were reviewed in 2019 at CUMC (n = 538). (A) The diagnosis of acute rejection was more commonly seen in COVID-19 patients (OR = 3.5, p = .047). When the type of rejection was assessed, it became clear that the difference was attributed to acute T cell–mediated rejection (OR = 4.7, p = .03) and mainly to acute vascular rejection (OR = 11.6, p = .002) (B) When Banff scores for acute rejection were analyzed, it became apparent that the strongest difference was detected upon comparing arteritis scores (p < .001) followed by glomerulitis scores (p = .02). The latter need to be interpreted with caution since severe glomerulitis in one case is likely attributed to the presence of masked deposits. Of note, five general for cause allograft kidney biopsies had negative C4d staining in peritubular capillaries with histologic evidence of acute antibody-mediated tissue injury and evidence of current/recent evidence of antibody interaction with vascular endothelium but without available data on concurrent DSA. These five biopsies were classified as AMR. AMR, antibody-mediated rejection; Bxs, biopsies; KTx, kidney transplant; TCMR, T cell–mediated rejection (*p < .05; for more detailed analysis, please refer to Table S3)
patients displayed persistent renal dysfunction. In no case did we find evidence of direct viral infection of the allograft kidney either by immunohistochemistry, in situ hybridization, or electron microscopy.

The most common cause of allograft dysfunction in our series was acute rejection. Histologic evidence of acute rejection in the setting of COVID-19 has been previously documented. In two of the cases reported by Akilesh et al., an increase in DSA levels was noted around the time of allograft biopsy. In our series, three of the five patients who showed evidence of an acute rejection after COVID-19 had documented DSAs around the time of biopsy. This suggests the possibility that SARS-CoV-2 virus acts as a “second” hit in the setting of preexisting DSAs to trigger acute rejection. Although none of the five rejecting patients in our study had a documented decrease in their immunosuppression prior to the biopsy procedure, two had low tacrolimus levels between development of COVID-19 and allograft biopsy. Therefore, the possibility of acute rejection triggered by inadequate immunosuppression cannot be excluded in these two patients. Nevertheless, a high proportion of patients who had COVID-19 within 1 month of allograft biopsies developed acute rejection, especially acute vasculitis. In conclusion, this series provides new insight into the factors underlying kidney injury in the kidney transplant population after SARS-CoV-2 infection. The close temporal associations with acute rejection implicate roles for heightened adaptive and innate immune responses.

ACKNOWLEDGMENTS
The authors thank Yuancheng Wang, Maria Lourdes Diaz Belvis, and the Immunohistochemistry Laboratory at Columbia University Irving Medical Center for their excellent technical assistance.

DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author after obtaining an IRB approval. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Emily Daniel https://orcid.org/0000-0002-5690-4661
Miroslav Sekulic https://orcid.org/0000-0002-7938-1816
Satoru Kudohttps://orcid.org/0000-0001-8396-9877
Xiaoyi Ye https://orcid.org/0000-0001-5685-7239
Ankita Patel https://orcid.org/0000-0001-5084-2490
David J. Cohen https://orcid.org/0000-0003-1227-3252
Dominick Santoriello https://orcid.org/0000-0001-5854-4236
M. Barry Stokes https://orcid.org/0000-0003-0958-7672
Marcus R. Pereira https://orcid.org/0000-0002-9214-9122
Ibrahim Batal https://orcid.org/0000-0002-0686-5457

REFERENCES
1. Kudo S, Batal I, Santoriello D, et al. Kidney biopsy findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):1959-1968.
2. Golmai P, Larsen CP, DeVita MV, et al. Histopathologic and ultrastructural findings in postmortem kidney biopsy material in 12 patients with AKI and COVID-19. J Am Soc Nephrol. 2020;31(9):1944-1947.
3. Santoriello D, Khairallah P, Bombback AS, et al. Postmortem kidney pathology findings in patients with COVID-19. J Am Soc Nephrol. 2020;31(9):2158-2167.
4. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype. J Am Soc Nephrol. 2020;31(8):1688-1695.
5. Sharma P, Uppal NN, Wanchoo R, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J Am Soc Nephrol. 2020;31(9):1948-1958.
6. Lazareth H, Perê H, Binois Y, et al. COVID-19-related collapsing glomerulopathy in a kidney transplant recipient. Am J Kidney Dis. 2020;76(4):590-594.
7. Jespersen Nizamic T, Huang Y, Alnimri M, Cheng M, Chen LX, Jen KY. COVID-19 manifesting as renal allograft dysfunction, acute pancreatitis, and thrombotic microangiopathy: a case report. Transplant Proc. 2021;53(4):1211-1214.
8. Westhoff TH, Seibert FS, Bauer F, et al. Allograft infiltration and meningoencephalitis by SARS-CoV-2 in a pancreas-kidney transplant recipient. Am J Transplant. 2020;20(11):3216-3220.
AJT

9. Doevelaar AAN, Hölzer B, Seibert FS, et al. Lessons for the clinical nephrologist: recurrence of nephrotic syndrome induced by SARS-CoV-2. J Nephrol. 2020;33(6):1369-1372.

10. Noble R, Tan MY, McCulloch T, et al. Collapsing glomerulopathy affecting native and transplant kidneys in individuals with COVID-19. Nephron. 2020;144(11):589-594.

11. Yamada M, Rastogi P, Ince D, et al. Minimal change disease with nephrotic syndrome associated with coronavirus disease 2019 after apolipoprotein L1 risk variant kidney transplant: a case report. Transplant Proc. 2020;52(9):2693-2697.

12. Oniszczuk J, Moktefi A, Mausoleo A, et al. De novo focal and segmental glomerulosclerosis after COVID-19 in a patient with a transplanted kidney from a donor with a high-risk APOL1 variant. Transplantation. 2021;105(1):206-211.

13. Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19-associated glomerular disease. J Am Soc Nephrol. 2021;32(1):33-40.

14. Webb C, Davidson B, Jones ESW, et al. COVID-19-associated graft loss from renal infarction in a kidney transplant recipient. Kidney Int Rep. 2021;6(4):1166-1169.

15. Akilesh S, Nast CC, Yamashita M, et al. Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria. Am J Kidney Dis. 2021;77(1):82-93 e81.

16. Man Z, Jing Z, Huibo S, Bin L, Fanjun Z. Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia. Am J Transplant. 2020;20(9):2626-2627.

17. Silvano J, Ferreira F, Bustorff M, et al. Viral clearance and serological response to SARS-CoV-2 in kidney transplant recipients. Transplant Proc. 2021;53(4):1180-1186.

18. World Health Organization. COVID-19 clinical management: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1. Accessed May 15, 2021.

19. Batal I, Serban G, Mohan S, et al. The clinical significance of receiving a kidney allograft from deceased donor with chronic histologic changes. Mod Pathol. 2021;34(9):1795-1805.

20. Elias M, Pievani D, Randoux C, et al. COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes. J Am Soc Nephrol. 2020;31(10):2413-2423.

21. Chavarot N, Ouedrani A, Marion O, et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation. 2021;105(9):e94-e95.

22. Benotmane I, Gautier-Vargas G, Cognard N, et al. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. Kidney Int. 2021;99(6):1487-1489.

23. Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol. 2020;16(10):565-567.

24. Santoriello D, Husain SA, De Serres SA, et al. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int. 2018;94(6):1189-1198.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Daniel E, Sekulic M, Kudose S, et al. Kidney allograft biopsy findings after COVID-19. Am J Transplant. 2021;21:4032-4042. https://doi.org/10.1111/ajt.16804